SCHAUMBURG, Ill., Jan 7 (Bernama-BUSINESS WIRE) — Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today provided an update on recent business highlights and financial performance for 2024 and strategic priorities for 2025 ahead of the Company’s participation in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025 in San Francisco, CA.
“2024 was a breakout year for Avenacy marked by exceptional growth and tremendous progress. Through our industry-leading speed to market and steadfast commitment to quality, safety, and reliability, we have demonstrated our value as a clear partner of choice for hospitals and providers in need of essential medications,” said Jeff Yordon, Co-Founder & CEO of Avenacy. “2025 will be a pivotal year for the organization, and we are confident in our ability to achieve our ambitious portfolio and broader business goals. As we continue to position our business for accelerated growth, we remain committed to our mission of enhancing patient care and addressing critical gaps in the U.S. healthcare system.”